Hogan & Hartson
Hogan Lovells is an international law firm co-headquartered in London, United Kingdom and Washington, D.C., United States. It was formed on May 1, 2010 following the merger of Washington-based Hogan & Hartson and London-based Lovells. The two firms' agreement to merge was announced on 15 December 2009. Hogan Lovells has around 2,500 lawyers and revenues of around US$1.8bn (£1.1bn).
Figures are based on itemized contributions reported to the Federal Election Commission and state agencies. Please note that:
- contributions under $200 are not reported, and so are not included in totals.
- only contributions from individuals and organizations to candidates are included. Various accounting measures and more exotic contribution types are excluded.
- contributions are matched based on organization and recipient name reported within each election cycle. Contributions using an incorrect or non-standard version of the name may be missed.
- corporate name changes and mergers may cause figures to differ from those of the Center for Responsive Politics.
- organization totals include known subsidiaries of the organization.
Latest FEC Datacovers through committee's December 31, 2010 filing.
Summaryoverview of the committee's finances
- Total Raised:
- Total Spent:
- Cash on Hand:
Standardized Donation Informationcovers roughly through Q4 2012. may lag behind FEC section above, as donors and industries are identified by hand.
- Employee Color Block
- PAC Color Block
Republicans vs. Democratsin dollars. "Other" includes 3rd parties and organizations without official party affiliation.
State vs. Federalin dollars
Top PAC Recipients
- Employee Color Block
- PAC Color Block
Bundled ContributionsMoney raised by the firm from multiple donors on behalf of the recipient. The firm's own contributions are not included.
Recipient Lobbyist Amount National Republican Senatorial Cmte Jeffrey W. Munk $61,800
Figures are based on lobbying activity reported to the Senate Office of Public Records. Reported dollar amounts are required to be accurate only to the nearest $20,000. For organizations whose primary business is lobbying, we display total income and top clients. For organizations that are not primarily lobbying firms, we display total amount spent on lobbying and top lobbying firms hired.
For more information, please see our lobbying methodology page.
Lobbying Carried Out by Hogan & Hartson
Names of Lobbyists
Client Amount Nissan North America $2,300,000 Anschutz Corp $520,000 TPG $510,000 SICPA Product Security $450,000 Maples & Calder $440,000 Northwestern University $440,000 Yurok Tribe $420,000 Forthright $420,000 LiveOps Inc $400,000 Intrepid Potash $380,000
Most Frequently Disclosed Lobbying Issues
- Fed Budget & Appropriations,
- Energy & Nuclear Power,
- Health Issues,
- Medicare & Medicaid,
- Food Industry,
- Medical Research & Clin Labs,
- Environment & Superfund
Most Frequently Disclosed Bills
Bill No. Title H.R.1 American Recovery and Reinvestment Act of 2009 H.R.2454 American Clean Energy And Security Act of 2009 H.R.1256 Family Smoking Prevention and Tobacco Control Act H.R.1105 Legislative Branch Appropriations Act, 2009 S.1462 American Clean Energy Leadership Act of 2009 S.506 Stop Tax Haven Abuse Act H.R.915 FAA Reauthorization Act of 2009 H.R.1409 Employee Free Choice Act of 2009 S.510 FDA Food Safety Modernization Act S.539 Clean Renewable Energy and Economic Development Act
RegulationsMentioned in 38 dockets; Submitted to 5 dockets
All data is based on documents downloaded from Regulations.gov. The first table shows mentions: all documents that include the name of the company anywhere in the document or document metadata. The second table shows submissions: all documents where the submitter metadata included the company name. Each table shows the top 10 dockets, ranked by number of occurrences.
Matches are based on a search for the company name. Variations in the company name, such as acronyms, nicknames or alternate names may cause documents to be missed. The mention of a company name in a document may be incidental and does not necessarily indicate that the company has any relevance to the document. Company names that are common English words may erroneously match with text that is not referring to the company.
Not all agencies submit public comments to Regulations.gov. For a list of participating and non-participating agencies see here. Agencies that do submit to Regulations.gov have varying levels of accuracy and completeness.
Regulations and public comments can be downloaded in bulk here.
The tables show occurrences of "Hogan & Hartson" in public comments on proposed federal regulations.
Documents Submitted by the Organization
View all submissions data for Hogan & Hartson
- Toggle 1 IRS Damages Received on Account of Personal Physical Injuries or Physical Sickness 2009
- Toggle 1 NHTSA Petition For Rulemaking 2009
- Toggle 1 SBA American Recovery and Reinvestment Act: Revised SBIC Maximum Leverage Limits 2009
- Toggle 1 PHMSA Hazardous Materials Revision to Requirements for the Transportation Lithium Batteries 2009
- Toggle 1 FDA Promotion of FDA-Regulated Medical Products Using the Internet and Social Media Tools; Notice of Public Hearing 2009
Mentions in Document Text
View all mentions data for Hogan & Hartson
- Toggle 7 EPA North Dakota Regional Haze State Implementation Plan 2010
- Toggle 7 FAA Valley Aviation Services, LLP, an Arizona Limited Liability, Partnership v. City of Glendale, an Arizona Charter City 2009
- Toggle 6 FDA Patent Term Extension Application for VIMPAT® (lacosamide) Tablet, U.S. Patent No. 5,654,301, NDA 22-253 2009
- Toggle 5 FDA U.S. Patent Term Extension Application for VIMPAT® (lacosamide) Tablet, U.S. Patent No. RE38,551, NDA 22-253 2009
- Toggle 5 EPA Finding of Substantial Inadequacy of Implementation Plan; Call for Utah State Implementation Plan Revision 2010
- Toggle 5 FDA Patent Term Extension Application for VIMPAT® (lacosamide) Injection, U.S. Patent No. RE38,551, NDA 22-254 2009
- Toggle 5 FDA Patent Term Extension Application for VIMPAT® (lacosamide) Injection, U.S. Patent No. 5,654,301, NDA-22-254 2009
- Toggle 5 FDA Patent Term Extension Application for PRISTIQ™ (desvenlafaxine sucinate), U.S. Patent No. 6,673,838 2009
- Toggle 5 FDA Patent Term Extension Application for PRISTIQ™ (desvenlafaxine sucinate), U.S. Patent No. 7,291,347 2009
- Toggle 4 FDA Petition Requesting that the Agency not Approve ANADA 011-557 Before Expiration of the 30-month Stay on March 29, 2011 2009
Advisory Committees2 people on 3 committees
Data is based on disclosures required by the Federal Advisory Committee Act (FACA). Matches are based on the occurrence of the company name in the committee member affiliation. Variations in company names may cause some matches to be missed.
The table shows only the top 10 agencies. To search and download raw records from the complete dataset see the FACA data section.
Table shows employees of "Hogan & Hartson" that sat on federal advisory committees.
- Toggle Department of the Interior 2 people on 2 committees
- Toggle Office of the United States Trade Representative 1 person on 1 committee